In the past, the prophylactic use of granulocyte-colony stimulating factor (G-CSF) drugs such as filgrastim (3) and pegfilgrastim (4) has been frequently applied for patients at a high or intermediate risk during chemotherapy of various cancers and shown to greatly reduce the incidence of FN (5, 6). The gene discussed is CSF3; the disease is cancer.